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Abstract
Background: Nef is an HIV-1 accessory protein essential for viral replication and AIDS progression. Nef interacts
with a multitude of host cell signaling partners, including members of the Src kinase family. Nef preferentially
activates Hck, a Src-family kinase (SFK) strongly expressed in macrophages and other HIV target cells, by binding to
its regulatory SH3 domain. Recently, we identified a series of kinase inhibitors that preferentially inhibit Hck in the
presence of Nef. These compounds also block Nef-dependent HIV replication, validating the Nef-SFK signaling
pathway as an antiretroviral drug target. Our findings also suggested that by binding to the Hck SH3 domain, Nef
indirectly affects the conformation of the kinase active site to favor inhibitor association.
Results: To test this hypothesis, we engineered a “gatekeeper” mutant of Hck with enhanced sensitivity to the
pyrazolopyrimidine tyrosine kinase inhibitor, NaPP1. We also modified the RT loop of the Hck SH3 domain to
enhance interaction of the kinase with Nef. This modification stabilized Nef:Hck interaction in solution-based kinase
assays, as a way to mimic the more stable association that likely occurs at cellular membranes. Introduction of the
modified RT loop rendered Hck remarkably more sensitive to activation by Nef, and led to a significant decrease in
the Km for ATP as well as enhanced inhibitor potency.
Conclusions: These observations suggest that stable interaction with Nef may induce Src-family kinase active site
conformations amenable to selective inhibitor targeting.
Background
Nef is an HIV-1 accessory protein that facilitates virus
infectivity, replication, and immune evasion [1-3]. In
non-human primate models of AIDS, high-titer viral
replication and development of AIDS-like disease
requires an intact Nef gene [4]. Long-term non-progres-
sive HIV infection in humans is also associated with
Nef-defective HIV isolates in some cases [5,6]. Comple-
mentary in vivo studies have shown that directed
expression of Nef alone to HIV target cells induces an
AIDS-like syndrome in transgenic mice [7-9]. Taken
together, these studies underscore the importance of
HIV-1 Nef in AIDS pathogenesis.
Nef is not known to exhibit any intrinsic enzymatic
activity. Instead, Nef interacts with multiple host cell
signaling pathways to enhance HIV-1 replication and
promote AIDS progression [10]. Previous work from
our group has identified members of the Src kinase
family as direct Nef effectors [11-15]. This kinase family
includes Hck, a Src-family member expressed in macro-
phages, which are a critical HIV target cell type and
viral reservoir. Nef interacts with the Hck SH3 domain,
leading to constitutive Hck activation that may contri-
bute to macrophage survival, MHC-I downregulation
and M-tropic HIV replication [11,12,14,16-18]. Nef has
also been shown to bind and activate the Src-family
kinases Lyn and c-Src, which exhibit a broader expres-
sion pattern including other HIV target cell types [14].
Thus, Nef-dependent activation of Src family kinases is
likely to occur in most HIV-infected cells.
Hck shares a similar domain organization and struc-
tural architecture with other members of the Src kinase
family [19-21]. Key structural features include an N-
terminal unique domain with sites for lipid attachment
that drive membrane association, followed by the regula-
tory SH3 and SH2 domains, an SH2-kinase linker, the
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kinase domain, and a C-terminal negative regulatory tail.
Nef binds to the Hck SH3 domain through a bipartite
mechanism revealed in structural analyses of Nef:SH3
complexes [22-25]. Nef:SH3 interaction is dependent in
part on a highly conserved PxxPxR motif, which forms a
polyproline type II helix typical of most SH3 ligands. In
addition, the aA and aB helices of Nef form a hydro-
phobic pocket that interacts with an Ile residue in the
RT loop of the SH3 domain. Nef binding displaces the
SH3 domain from its negative regulatory position on
the back of the kinase domain, leading to kinase activa-
tion. Interestingly, mutation of the Nef PxxPxR motif
completely abolished development of the AIDS-like phe-
notype in Nef-transgenic mice [8]. Furthermore, cross-
ing Nef transgenic mice into a hck-null background
increased the latency for AIDS-like disease onset and
decreased mortality [8]. These data provide strong evi-
dence that Src-family kinase activation by Nef is impor-
tant for AIDS pathogenesis, and identify this signaling
pathway as a target for therapeutic intervention.
Recently, we developed a chemical library screening
assay based on Nef-dependent activation of Hck in vitro
[15]. Using this assay, we identified a series of diphenyl-
furopyrimidine (DFP) analogs that preferentially inhibit
Hck in the presence of Nef. These compounds also
potently blocked HIV-1 replication in a Nef-dependent
manner [15], validating inhibitors of Nef-SFK signaling
as potential antiretroviral agents. Our observation that
DFP-based kinase inhibitors selectively inhibit the Nef:
Hck complex suggested that Nef binding to the Hck
SH3 domain induces structural changes in the kinase
domain that favor inhibitor association. In the present
study, we developed a system to test this hypothesis
directly using a “gatekeeper” mutant of Hck with engi-
neered sensitivity to the pyrazolopyrimidine analog,
NaPP1 [26,27]. This mutation involves substitution of
the gatekeeper threonine (Thr338; numbering as per c-
Src crystal structure [28]) with a much smaller alanine
residue (Hck-TA mutant), providing access for NaPP1
to the hydrophobic cavity adjacent to the ATP binding
site. This combination of mutant kinase and NaPP1
results in a high degree of inhibitor selectivity and
potency both in vitro and in cell-based assays [27].
Because NaPP1 binds to the Hck-TA active site in a
specific location, it serves as a chemical probe for con-
formational changes that may occur in response to Nef
binding. In addition to the gatekeeper mutation, we
modified the SH3 domain to enhance interaction with
Nef [29,30]. This modification enabled stable association
of Hck with Nef in solution-based kinase assays, thus
mimicking the stable association that is likely to occur
between Hck and Nef at cellular membranes [17]. Use
of this modified form of Hck combined with the selec-
tive inhibitor enabled us to demonstrate that Nef
binding results in changes in the Km for ATP as well as
inhibitor potency. These observations support the idea
that Nef binding induces a unique active conformation
of the Hck active site that can be targeted with selective
inhibitors.
Methods
Recombinant protein expression and purification
Nef-SF2 and Nef-Consensus for kinase assays were
expressed in E. coli with hexahistidine tags and purified
by immobilized metal affinity chromatography (IMAC)
as described elsewhere [14]. For SPR experiments, the
same two Nef proteins were purified without N-terminal
His tags by anion-exchange chromatography (HiPrep Q
FF; GE Healthcare). Both the His-tagged and untagged
Nef proteins were further purified by gel filtration chro-
matography on a HiLoad 26/60 Superdex 75 column
(GE Healthcare) with 20 mM Tris-HCl, pH 8.3, 100
mM NaCl and 3 mM DTT as mobile phase.
A cDNA clone for mouse Hck (mHck) was modified
at its gatekeeper position (Thr338) with alanine, the C-
terminal tail was changed to the autoregulatory
sequence, Tyr-Glu-Glu-Ile (YEEI), and the N-terminal
unique domain was replaced with a hexahistidine tag as
described previously for human Hck [27]. The coding
sequence for the High Affinity RT loop (HART) was
then introduced by replacing the wild-type SH3 RT loop
sequence EAIHRE with TSPFPW using site-directed
mutagenesis [30]. The presence of all changes was con-
firmed by DNA sequence analysis of the entire Hck
open reading frame. The mHck-T338A-YEEI (mHck-
TA) and the mHck-T338A-HART-YEEI (mHck-TA-
HART) coding sequences were subcloned into the bacu-
lovirus transfer vector pVL1392 (BD Biosciences) and
the resulting plasmids used to create high-titer recombi-
nant baculoviruses in Sf9 insect cells using Baculogold
DNA and the manufacturer’s protocol (BD Biosciences).
Recombinant mHck proteins were expressed in Sf9
insect cells and purified using a combination of ion-
exchange and IMAC chromatography as described pre-
viously for human Hck [27]. Following purification, the
mHck proteins were dialyzed against 20 mM Tris-HCl,
pH 8.3, containing 100 mM NaCl and 3 mM DTT. The
purity and concentration of each recombinant protein
were confirmed by SDS-PAGE, densitometry and elec-
trospray mass spectrometry.
The sequences encoding the wild-type hHck SH3
domain, mHck SH3 domain, and mHck SH3-HART
mutant were amplified by PCR and subcloned into the
bacterial expression vector, pET-14b (mHck SH3s) or
pET-21a (hHck SH3). All three SH3 proteins were
expressed in E. coli BL21(DE3)pLysS in the presence of
0.4 mM IPTG for 4 h at room temperature. Cells were
sonicated in lysis buffer (20 mM Tris-HCl, pH 8.3, 10%
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glycerol, and 5 mM 2-mercaptoethanol), and soluble
SH3 proteins were purified from clarified cell lysates
using a combination of anion-exchange (HiPrep Q FF;
GE Healthcare), IMAC (HiTrap Chelating HP; GE
Healthcare), and size-exclusion chromatography (HiLoad
26/60 Superdex 75; GE Healthcare). Purified SH3 pro-
teins were stored in 20 mM Tris-HCl, pH 8.3, 100 mM
NaCl and 3 mM DTT. SH3 protein purity and concen-
tration were confirmed by SDS-PAGE, densitometry and
mass spectrometry.
Hydrogen exchange mass spectrometry (HXMS)
HXMS was used to investigate Nef:SH3 interaction as
described [31] with the following modifications. Recom-
binant Hck SH3 and Nef proteins were equilibrated
together at 4°C for at least 110 min before the initiation
of the labeling reaction. Starting reactions consisted of
the SH3 (50 μM) and Nef (117 μM) proteins in 20 mM
Tris-HCl, pH 8.3, 100 mM NaCl, and 3 mM DTT. Deu-
terium labeling was initiated by 15-fold dilution of the
binding reaction into D2O labeling buffer (20 mM Tris,
pD 8.3, 100 mM NaCl, 3 mM DTT). Labeled proteins
were injected onto a POROS 20 R2 protein trap and
desalted with 0.05% trifluroacetic acid (TFA) at a flow
rate of 500 μL/min. The proteins were eluted into the
mass spectrometer using a linear 15% to 75% (v/v) acet-
onitrile gradient over 4 min at 50 μL/min with a Shi-
madzu HPLC system (LC-20AD). HPLC was performed
using protiated solvents which results in the removal of
deuterium from the side-chains and the amino/carboxy
termini which exchange faster than backbone amide
hydrogen atoms [32,33]. Mass spectral analyses were
carried out with a Waters LCT-PremierXE mass spectro-
meter with a standard electrospray source, a capillary
voltage of 3.2 kV and a cone voltage of 35 V. The deu-
terium levels were not corrected for back-exchange [32]
and reflect relative changes across the protein samples.
The isotope envelopes in bimodal patterns were fit with
two Gaussian functions whose widths were estimated
from a single binomial isotopic envelope before and
after the appearance of the bimodal pattern. The unfold-
ing rates for those SH3 domains that presented evidence
of a bimodal isotopic envelope were determined from
the slope of pseudo-first-order kinetic plots of the
decrease in the relative intensity of the lower mass
envelope with time [34-36].
In vitro kinase assay
Protein-tyrosine kinase assays were performed using the
FRET-based Z’-Lyte kinase assay kit and Tyr-2 peptide
substrate according to the manufacturer’s instructions
(Life Technologies) and our previous work [14,15,27,37].
All assays were performed in quadruplicate in low-
volume, non-binding 384-well plates (Corning). To
determine the Km for ATP, time course experiments
were run at fixed concentrations of substrate (1 μM)
and kinase in the presence of an ATP concentration
range from 0 to 500 μM. The Km for ATP was then cal-
culated from a plot of ATP concentration against initial
reaction velocity followed by non-linear regression ana-
lysis (GraphPad Prism). For inhibition experiments, the
assay was first optimized to determine the amount of
kinase or kinase plus Nef (1:10 molar ratio) necessary to
phosphorylate ~50% of the Tyr-2 peptide substrate in
the presence of an ATP concentration equal to twice
the Km. Kinases were pre-incubated with NaPP1 in
kinase assay buffer (50 mM Hepes, pH 7.5, 10 mM
MgCl2, and 1 mM EGTA, 0.01% Brij-35) for 30 min, fol-
lowed by incubation with ATP and Tyr-2 peptide for 1
h at room temperature. Development reagent was then
added to the reaction for an additional 1 h at room tem-
perature, followed by addition of the stop reagent.
Fluorescence was assessed at an excitation wavelength
of 400 nm; coumarin fluorescence and the fluorescein
FRET signal were monitored at 445 and 520 nm, respec-
tively. Reactions run in the absence of ATP served as
the 0% phosphorylation control, whereas a stoichiome-
trically phosphorylated Tyr2 peptide was used as the
100% phosphorylation control. Raw fluorescence values
were corrected for background, and reaction endpoints
calculated as emission ratios of coumarin fluorescence
divided by the fluorescein FRET signal. These ratios
were normalized to the ratio obtained with the 100%
phosphorylation control peptide. IC50 values were calcu-
lated using a sigmoidal curve fit using GraphPad Prism.
Additional details of the Z’-Lyte assay principle and cal-
culation of percent inhibition has been described else-
where [15,27].
Surface plasmon resonance (SPR)
Recombinant Hck SH3 domain proteins were exchanged
into HBS-EP buffer (10 mM HEPES, pH 7.4, 150 mM
NaCl, 3 mM EDTA, 0.05% v/v P20 surfactant) and con-
centrated with an Amicon Ultra 15 ml 3 kDa molecular
weight cutoff spin concentrator. Primary untagged Nef
proteins were exchanged into HBS-EPD buffer (10 mM
HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% v/v
P20 surfactant, 1 mM DTT) and concentrated with an
Amicon Ultra 15 ml 10 kDa molecular weight cutoff
spin concentrator. SPR analysis was performed on a
BIAcore 3000 instrument (GE Healthcare) using a four-
channel CM5 biosensor chip with the Hck SH3 domains
covalently attached as ligand via standard amine cou-
pling chemistry [38,39]. Nef proteins (as analyte) were
flowed past the immobilized SH3 proteins on the bio-
sensor chip at a flow rate of 10 μl/min for 5 min using
Nef protein concentrations above and below the KD (see
Table 1). The initial binding reaction was followed by
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dissociation for 5 min, and the chip surface was regener-
ated using HBS-EPD buffer at a flow rate of 30 μl/min
for 10 min. Binding curves recorded at each analyte
concentration were assessed in triplicate, corrected for
buffer effects, and fit to a 1:1 Langmuir binding model
using the BIAevaluation 4.1 software suite (GE
Healthcare).
Results and discussion
Expression and characterization of a mouse Hck
gatekeeper mutant
Previous studies have shown that Nef forms a stable
complex with Hck in cells, and that this interaction
results in constitutive Hck activation [19]. As described
in the Background section, association with Nef may
influence the structure of the Hck kinase domain active
site, inducing a unique conformation amenable to selec-
tive inhibitor targeting. In order to test this idea, we
engineered the active site of mouse Hck (mHck) to
accommodate the pyrazolopyrimidine inhibitor, NaPP1
(Figure 1A). This modification involved substitution of
the gatekeeper position (Thr338) with alanine (referred
to hereafter as mHck-TA), which has been proposed to
provide access for NaPP1 to the hydrophobic cavity
adjacent to the ATP binding site [26,41-43]. The use of
kinase domain gatekeeper mutants in combination with
NaPP1 has been successfully applied in several kinase
systems [26,41-45], including previous work from our
group with human Hck [27].
To illustrate this chemical genetic concept, we mod-
eled the gatekeeper alanine substitution using previous
X-ray crystal structures of near-full-length downregu-
lated Hck with either the ATP analog AMP-PNP or the
NaPP1 analog PP1 bound to the active site [20,21]. As
shown in Figure 1B, alanine substitution of the gate-
keeper position does not appear to influence kinase
interaction directly with ATP. In contrast, when NaPP1
is overlaid via the corresponding pyrazolopyrimidine of
PP1, the more bulky naphthyl substituent of NaPP1
clashes with Thr338 (Figure 1C). This clash is likely to
be relieved by alanine substitution at this position
because of the much smaller side chain. That said, addi-
tional conformational changes in this region are likely to
be required to accommodate NaPP1 (see legend to Fig-
ure 1). Nevertheless, this model provides a useful frame-
work for understanding the relationship of the
gatekeeper substitution to NaPP1 sensitivity. More
importantly, these mHck-TA gatekeeper mutants
enabled use of NaPP1 as a specific chemical probe for
this region of the kinase domain active site. This specific
kinase-inhibitor pair allowed us to ask whether HIV-1
Nef binding to the SH3 domain influences the structure
of the kinase domain as described below.
Nef does not influence wild-type mHck-TA ATP binding
or competitive inhibition in solution-based kinase assays
We next expressed and purified recombinant mHck-TA
with a modified C-terminal tail (YEEI), which facilitates
expression and purification of the kinase in the downre-
gulated conformation [20,46]. The Km for ATP was then
assayed in the absence or presence of a 10-fold molar
excess of two allelic variants of Nef (B-clade alleles SF2
and Consensus) using an in vitro kinase assay (Z’-Lyte)
and a FRET-peptide substrate [27]. As shown in Table
2, the presence of Nef did not significantly affect the Km
for ATP under these conditions.
We next performed control experiments to confirm
that mHck-TA was sensitive to Nef-mediated activation
in this assay. mHck-TA was assayed either alone or in
the presence of a 10-fold molar excess of each Nef pro-
tein over a wide range of kinase concentrations. As
shown in Figure 2A and 2B, both forms of Nef markedly
shifted the mHck-TA activation curve to the left,
demonstrating that Nef activates mHck in a manner
quite similar to human Hck as previously reported with
this assay [14,15]. Based on these results, we identified
Table 1 Evaluation of Nef binding to wild-type and HART SH3 domains by surface plasmon resonance (SPR).
SH3 domain ka (M
-1s-1) × 105 kd (s
-1) × 10-2 KD (μM) Nef concentrations (μM)
Nef-SF2
Human Hck SH3 1.60 ± 0.06 1.18 ± 0.04 0.07 ± 0.01 0, 0.007, 0.02, 0.062, 0.19, 0.56, 1.67, 5.0
Mouse Hck SH3 5.54 ± 1.77 7.00 ± 0.36 0.13 ± 0.03 0, 0.007, 0.02, 0.062, 0.19, 0.56, 1.67
Mouse Hck HART 14.20 ± 1.40 1.43 ± 0.01 0.01 ± 0.00 0, 0.002, 0.007, 0.02, 0.062, 0.19
Nef-Consensus*
Human Hck SH3 10.00 ± 0.80 11.80 ± 0.20 0.12 ± 0.01 0, 0.02, 0.062, 0.19, 0.56, 1.67, 5.0
Mouse Hck SH3 2.41 ± 0.05 1.85 ± 0.11 0.08 ± 0.01 0, 0.007, 0.02, 0.062, 0.19, 0.56, 1.67
Mouse Hck HART 15.70 ± 0.20 3.24 ± 0.16 0.02 ± 0.00 0, 0.002, 0.007, 0.02, 0.062, 0.19, 0.56
SPR analyses were performed with the recombinant purified Hck SH3 domains covalently attached to the biosensor chip, as described under Materials and
Methods. Each untagged, purified Nef protein analyte was serially injected and the Nef-Hck interaction monitored over the range of Nef concentrations shown
(SF2 and Consensus variants, as indicated). The kinetics and affinities of binding were determined by fitting the data to a 1:1 Langmuir binding model, with the
dissociation constants (KD) and error analysis calculated through the BIAevaluation 4.1 software suite.
*Consensus Nef is based on a sequence alignment of multiple B-clade Nef proteins [40].
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Figure 1 Models of the wild-type and gatekeeper mutants of Hck in the presence of the ATP analog, AMP-PNP, and the inhibitor,
NaPP1. A) Chemical structures of AMP-PNP and NaPP1. B) Molecular model of downregulated Hck bound to AMP-PNP. The overall structure
(left) shows the SH3 domain (red), the SH2 domain (blue), and the kinase domain (green). The active site is boxed, and enlarged on the right.
The upper right view shows the juxtaposition of the wild-type (WT) gatekeeper residue (T338) with AMP-PNP; the view on the lower right shows
the gatekeeper mutant in which Thr338 is replaced with alanine (TA). This model was produced by docking the structure of Hck-YEEI (1QCF) [20]
onto an earlier structure of Hck bound to AMP-PNP (1AD5) [21]. C) Model of Hck bound to NaPP1. The overall structure is shown on the left,
and is color-coded as in Part B. Close-up views of the NaPP1 binding site are shown on the right. Note that NaPP1 clashes with the side chain
of the gatekeeper residue in this model (arrow; upper right), but this is relieved in the TA mutant (lower right). While the gatekeeper substitution
relieves one potential steric clash with the naphthyl moiety of NaPP1, other structural changes are likely to be required to accommodate
inhibitor binding. For example, the side chain of the alanine residue immediately adjacent to the DFG motif (Ala403; not shown) also clashes
with NaPP1, but this clash could be relieved by movement of the DFG motif to the “out” conformation associated with kinase activation. In this
case, the hydrophobic cavity would be enlarged and better able to accommodate the naphthyl moiety of NaPP1 in a horizontal orientation
relative to the model shown in Figure 1C. Ultimately, an X-ray crystal structure of Hck-TA with NaPP1 bound will be required to fully understand
the inhibitory mechanism. This model was produced using the crystal coordinates for Hck-YEEI bound to PP1 (1QCF) [20], and docking the
NaPP1 structure onto the pyrazolopyrimdine moiety of PP1.
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assay conditions where Hck activity was 50% of maxi-
mum in either the presence or absence of Nef. We then
determined the IC50 value for NaPP1 while holding the
ATP concentration to twice the Km for each condition.
NaPP1 inhibited mHck-TA with equal potency in the
presence or absence of Nef (Figure 2C and Table 2).
Taken together, these initial observations suggested that
either Nef does not influence the interaction of Hck
with ATP or NaPP1, or that the proportion of Hck
molecules that remain in complex with Nef was rela-
tively low under these experimental conditions. Note
that recombinant mHck without the gatekeeper substi-
tution showed relatively low sensitivity to NaPP1 in
either the presence or absence of Nef under the same
conditions as mHck-TA (IC50 > 1000 nM; Table 2).
mHck SH3 domain RT-loop mutants display enhanced
affinity for HIV Nef
The data presented in the preceding section show that in
solution, activation of mHck-TA by Nef does not perturb
the Km for ATP or inhibitor binding. However, these
assay conditions do not reflect the situation in cells,
where membrane association is likely to stabilize Nef
binding to Hck. Indeed, persistent interaction of Nef and
Hck in cells has been recently been demonstrated using
FRET [17]. In contrast, when combined in solution, the
stability of the Nef:Hck complex is solely a function of
their concentrations. Thus, our inability to identify
changes in the Km for ATP or in the IC50 for NaPP1 fol-
lowing Nef-induced activation of mHck-TA may be due
to dissociation of the Hck:Nef complex in solution.
Table 2 HIV-1 Nef binding influences the Hck active site.
Condition Km, ATP (μM) IC50, NaPP1 (nM)
mHck alone 12.1 ± 2.0 > 1,000
mHck + Nef-SF2 14.8 ± 1.4 > 1,000
mHck-TA alone 62 ± 12.6 53.3 ± 8.2
mHck-TA + Nef-SF2 68 ± 10.7 47.4 ± 6.0
mHck-TA + Nef-Consensus 84 ± 3.5 37.6 ± 4.6
mHck-HART alone 105.2 ± 29.0 n.d.
mHck-HART + Nef-SF2 49.34 ± 5.8 n.d.
mHck-TA-HART alone 181 ± 28.7 8.5 ± 0.7
mHck-TA-HART + Nef-SF2 69 ± 17.6 2.4 ± 0.3
mHck-TA-HART + Nef-Consensus 76 ± 23.1 3.2 ± 0.2
The Km values for ATP and IC50 values for NaPP1 were determined using the
Z’Lyte assay (see Materials and Methods). Four forms of purified recombinant
mouse Hck (mHck) were used in these experiments: wild-type (mHck); mHck
with a modified SH3 domain high affinity RT loop for Nef binding (mHck-
HART); mHck with a wild-type SH3 domain and a kinase domain mutation
(T338A) that accommodates the inhibitor, NaPP1 (mHck-TA); and a double
mutant (mHck-TA-HART). Experiments with Nef contained the recombinant
purified viral protein at a 10-fold molar excess, and were performed with two
Nef B-clade variants (SF2 and Consensus) in most cases. n.d., not determined.
Figure 2 Nef-induced activation of mHck-TA. Recombinant
downregulated mHck-TA activity was assayed over a range of
kinase amounts in the presence of a 10-fold molar excess of
purified recombinant Nef-SF2 (A) or Nef-Consensus (B) using the
Z’Lyte method (see Materials and Methods). C) Inhibition of mHck-
TA by NaPP1 in the presence or absence of Nef. Recombinant
downregulated mHck-TA activity was assayed either alone or in the
presence of a 10-fold molar excess of purified recombinant Nef-SF2
or Nef-Consensus over the range of NaPP1 concentrations shown
using the Z’Lyte method (see Materials and Methods). All assays
were performed in quadruplicate and data are shown as mean ± S.
D. Each experiment was repeated twice and produced comparable
results in each case.
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In order to stabilize the association of Hck with Nef
for solution-based assays, we modified the SH3 domain
of mHck to enhance its affinity for Nef. As described
under Background, one essential determinant of SH3
binding by Nef involves a conserved PxxPxR motif
[22,23,47]. The affinity of the interaction between SH3
domains and their ligands is also modulated by residues
in the RT-loop of the SH3 domain and areas outside of
the PxxPxR motif in the ligand [30,48]. In the case of
Nef, structural studies have established that residues
from the Nef aA and aB helices form a hydrophobic
pocket that accommodates an isoleucine residue unique
to the RT loop of the Hck SH3 domain and the closely
related Src-family member, Lyn (modeled in Figure 3)
[22,23]. Based on these observations, Hiipakka et al.
engineered enhanced SH3 affinity for Nef using a
phage-display library of modified Hck SH3 domains that
carry random hexapeptide substitutions in their RT-
loops [30]. To increase the stability of the mHck:Nef
complex in our experimental system, we selected one
High Affinity RT-loop (HART) SH3 domain sequence
based on its enhanced affinity for Nef as reported in this
previous study [30]. In this SH3 domain, the wild-type
RT-loop sequence, E94AIHRE, was replaced with a com-
pletely different sequence, T94SPFPW (Figure 3).
Before introducing the HART SH3 variant into near
full-length mHck-TA, we first examined its conforma-
tional dynamics and interactions with Nef using hydro-
gen exchange mass spectrometry (HXMS). Wild-type
mHck SH3 and the HART variant were expressed in
bacteria and purified to homogeneity. Each SH3 domain
was then incubated with D2O for various periods of
time, resulting in exchange of backbone amide hydro-
gens in the protein with deuterium in the solvent
[33,50]. Amide hydrogen bonding retards deuterium
exchange and amide hydrogens with high accessibility to
solvent exchange more rapidly with deuterium than
those that are buried. The kinetics of exchange provides
Figure 3 Molecular models of HIV-1 Nef in complex with wild-type and high-affinity RT loop SH3 domains (SH3-HART). A) Molecular
model of HIV-1 Nef (cyan) in complex with the SH3 domain of Fyn (red) in which RT loop Arg96 was replaced with isoleucine (I96) to resemble
the Hck SH3 domain (PDB: 1EFN[22,49]). B) Close-up view of the wild-type interaction interface. SH3 domain RT loop Ile96 (red spheres) interacts
with conserved hydrophobic residues of Nef that form a hydrophobic pocket (F90, W113, Y120). The interaction is stabilized by ion pairing of
SH3 Asp100 (D100) and Nef Arg77 (R77) in the conserved PxxPxR motif (dotted lines). C) To enhance Nef interaction with SH3, the wild-type RT
loop sequence E94AIHRE was replaced with the sequence T94SPFPW, which was previously reported to result in high affinity Nef-SH3 interaction
[30]. The side chains of the six modified residues are modeled in green. Note that SH3-HART Phe97 (F97; green spheres) occupies the position of
I96 in the wild-type crystal structure. Recent crystallographic analysis of a related high affinity Nef-SH3 interface supports this model [29].
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detailed information on protein fluctuations in solution.
In addition, changes in the rate of protein unfolding or
refolding can be correlated with the strength of ligand
binding.
Previous HXMS studies of the human Hck SH3
domain have revealed slow partial unfolding under phy-
siological solution conditions [34]. Importantly, the
dynamics of Hck SH3 domain unfolding are significantly
slowed by ligand binding, particularly with Nef [34-36].
We therefore used HXMS to compare the wild-type and
HART variant of the mHck SH3 domain in terms of the
relative impact on cooperative unfolding, and hence
binding affinity, upon full-length Nef association. As
shown in Figure 4, Nef-Consensus decreased the unfold-
ing rate of the wild-type mHck SH3 domain by approxi-
mately 5.7-fold. In contrast, Nef induced nearly a 50-
fold decrease in the unfolding rate of the mSH3-HART
protein. Since interaction affinity directly correlates with
a proportional slowdown in the unfolding rate [19],
these results demonstrate that Nef has a significantly
higher affinity for mSH3-HART vs. the wild-type mSH3
domain. Note that in the absence of Nef, the half-lives
of unfolding for the wild-type and HART mSH3
domains were very similar, indicating that the RT-loop
modification did not influence the global dynamics of
the mSH3 structure, at least within the error of determi-
nation of the half-life of the unfolding event.
To explore the interaction of the wild-type and HART
forms of the mSH3 domain with Nef in more detail, we
turned to surface plasmon resonance (SPR) analysis.
This approach afforded real-time determination of on-
and off-rate constants as well as equilibrium dissociation
constants. Representative sensorgrams are shown in Fig-
ure 5, and the resulting binding constants are summar-
ized in Table 1. SPR analysis showed that the wild-type
mouse SH3 domain bound to both Nef-SF2 and Nef-
Consensus with similar affinities (0.13 vs. 0.08 μM,
respectively), consistent with literature values for the
human Hck SH3 domain with Nef-SF2 as determined
by isothermal titration calorimetry (ITC) [29]. Introduc-
tion of the HART sequence enhanced the affinity of
these interactions by 13-fold and 4-fold for Nef-SF2 and
Nef-Consensus, respectively. The larger change asso-
ciated with Nef-SF2 binding is reflected in an increase
in the association rate constant (2.5-fold) as well as a
decrease in the dissociation rate constant (nearly 5-fold).
In contrast, while the association rate constant for Nef-
Consensus was also enhanced with SH3-HART (6.5-
fold), the dissociation rate constant was essentially
unchanged (< 2-fold). The dramatic enhancement in
Hck SH3-HART interaction for Nef-SF2 observed by
SPR is consistent with a recent determination of Nef-
SF2 interaction with a similarly modified Hck SH3
domain by ITC (10 nM via SPR vs. 12 nM via ITC)
[29]. For comparative purposes, we also examined the
kinetics of human Hck SH3 binding to Nef, and found
that the KD values are similar to those observed for
mouse Hck SH3 domain (Table 1). In summary, the
increased affinity of SH3-HART for Nef observed by
SPR is consistent with the Nef-induced decrease in the
unfolding rate of SH3-HART determined by HXMS.
Data from both biophysical measurements support the
stabilization of Nef association with Hck for solution-
based kinase assays.
Figure 4 HXMS analysis reveals that HART substitution
enhances Nef:mSH3 domain interaction without influencing
mSH3 dynamics. The wild-type (WT) and HART mHck SH3 domains
were exposed to deuterium in the presence or absence of Nef.
Representative mass spectra showing an increase in m/z for the +6
charge state with increasing exposure time are presented for the
WT mSH3 domain alone (A) and bound to Nef (B), and for mSH3-
HART alone (C) and bound to Nef (D). An adduct peak (indicated by
an asterisk) is also observed in each spectrum. (E) Unfolding half-
lives for the SH3 domains both free and bound to Nef as well as
the calculated slowdown factors (SF). The slowdown factor is a
measure of the influence of Nef binding on the cooperative
unfolding rate of the SH3 domain, and is calculated by taking the
ratio of the unfolding half-life under different conditions as
described in Hochrein, et al. [51] All HXMS studies were performed
with Nef-Consensus.
Pene-Dumitrescu et al. BMC Chemical Biology 2012, 12:1
http://www.biomedcentral.com/1472-6769/12/1
Page 8 of 12
Introduction of SH3-HART sensitizes near full-length
mHck to activation by Nef
To determine the impact of the SH3-HART modifica-
tion in the context of near full-length Hck, we next
introduced the HART coding sequence into mHck-TA.
The resulting protein was expressed in Sf9 insect cells
and purified to homogeneity. Because the HART
sequence strongly enhanced interaction of the isolated
SH3 domain with Nef, we predicted that mHck-TA-
HART should be activated at lower concentrations of
Nef than mHck-TA with a wild-type SH3 domain. To
test this hypothesis, we conducted in vitro kinase assays
over a range of kinase:Nef ratios for both Nef variants.
As shown in Figure 6, maximal activation of mHck-TA-
HART was observed at a 1 to 1 ratio with Nef-SF2,
while full activation of mHck-TA required a 5-fold
excess of Nef-SF2. This enhancement in sensitivity
agrees with the increased affinity of Nef-SF2 for SH3-
HART (Table 1). Hck-TA-HART was also more sensi-
tive to activation by Nef-Consensus, although to a lesser
extent compared to Nef-SF2. This observation fits with
the smaller enhancement in SH3-HART binding to Nef-
Consensus as determined by SPR.
The enhanced activation of Hck-HART by Nef most
likely reflects the enhanced affinity of the modified SH3
domain for Nef. However, HART modification may also
reduce SH3 affinity for the SH2-kinase linker, thus
creating a partial destabilization of the downregulated
conformation of Hck. To control for this possibility, we
compared the basal activity of Hck-TA with and without
the HART substitution in the absence of Nef. We
observed that the specific activity of Hck-TA-HART was
Figure 5 Surface plasmon resonance (SPR) analysis of the Nef-
SH3 domain interaction. SPR analyses were performed with the
recombinant purified Hck SH3 domains indicated. The SH3 proteins
were covalently attached to the biosensor chip, and purified Nef
proteins (SF2 and Consensus variants) were serially injected over a
range of concentrations. The kinetics and affinities of binding were
determined by fitting the sensorgram data (black curves) to a 1:1
Langmuir binding model (red traces) using the BIAevaluation 4.1
software suite. Nef concentrations corresponding to each response
curve, along with the calculated binding constants, are presented in
Table 1.
Figure 6 SH3-HART substitution sensitizes mHck-TA to Nef-
induced activation. The relative kinase activities of mHck-TA and
mHck-TA-HART were determined in the absence or presence Nef at
each of the molar ratios shown. Experiments were performed with
recombinant Nef-SF2 (A) or Nef-Consensus (B) using the Z’-Lyte
kinase assay as described under Materials and Methods. All assays
were performed in quadruplicate, and the data are normalized to
the signal observed with a stoichiometrically phosphorylated control
peptide. Results are shown as mean percent of maximum ± S.D.
Both experiments were repeated twice and produced comparable
results in each case.
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less than two-fold higher than that of Hck-TA, consis-
tent with the idea that the enhanced sensitivity of Hck-
HART to Nef is primarily due its increased affinity for
Nef interaction (data not shown).
Stable interaction with Nef impacts the mHck active site
Data presented in the previous section demonstrate that
substitution of the wild-type mHck SH3 domain with
mSH3-HART dramatically enhances Nef binding affinity
for the SH3 domain, resulting in enhanced activation of
mHck in vitro. These observations demonstrate that
mHck-HART forms more stable complexes with Nef
than wild-type mHck, allowing us to return to the ques-
tion of whether Nef binding to the SH3 domain influ-
ences the Hck active site. We first determined whether
the Km of mHck-TA-HART for ATP was affected by
the presence of Nef. As shown in Table 2, the presence
of Nef significantly reduced the Km for ATP with
mHck-HART, and this effect was remarkably consistent
for both Nef variants tested (~2.5-fold reduction in each
case). A similar Km effect of Nef-SF2 was observed with
recombinant mHck-HART in the absence of the TA
mutation (Table 2). We next investigated whether the
presence of Nef also affected inhibition of the Hck-TA-
HART kinase by NaPP1, which occupies a binding site
adjacent to and overlapping with the ATP binding site
(modeled in Figure 1B). Here again, Nef-SF2 increased
the sensitivity of mHck-TA-HART to inhibition by
NaPP1 by more than three-fold (Table 2). Nef-Consen-
sus also increased the apparent potency of NaPP1, albeit
to a lesser extent. Together with the effect on the Km
for ATP, these data provide strong evidence that the
presence of Nef influences the conformation of the Hck
active site.
Conclusions
In the present study, we developed a modified form of
mHck that enabled an assessment of the impact of Nef
binding on the kinase active site under solution assay
conditions. Two important modifications were involved.
First, the kinase domain gatekeeper residue (Thr338)
was replaced with alanine, enabling site-specific inhibi-
tion with the pyrazolopyrimidine, NaPP1. Second, the
RT-loop of the SH3 domain was modified to enhance
Nef binding, thus promoting stable interaction in solu-
tion as demonstrated by SPR and HXMS. Using this
modified form of Hck, we showed that Nef caused a sig-
nificant decrease in the Km for ATP as well as an
increase in the apparent potency of the site-specific
inhibitor, NaPP1. These findings provide evidence that
Nef binding not only dislodges the SH3 domain from its
regulatory position on the back of the kinase domain,
but also influences the conformation of active site resi-
dues involved in ATP binding as well as inhibition by
NaPP1. Because Nef interacts with and activates Hck
through its SH3 domain, rather than through direct
interaction with the kinase domain, our results suggest
that Nef influences the conformation of active site
though an allosteric mechanism. Nef-mediated activa-
tion of Hck may alter the kinetics of kinase activity as
well as substrate selection. Data presented here also sug-
gest that this novel form of Hck will enable future high-
throughput chemical library screens for next-generation
compounds with enhanced specificity for the Nef:kinase
complex. While use of the modified form of Hck
described here may simplify high-throughput screening
of chemical libraries, future work must ultimately
address the sensitivity of myristoylated, full-length Nef
and Hck complexes to inhibitors in the context of biolo-
gical membranes.
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